An unprecedented Veterans Affairs (VA) research program that promises to advance the sophisticated science of genomics goes national today. “The Veterans Affairs Research and Development Program has launched the Million Veteran Program, or MVP—an important partnership between VA and Veterans to learn more about how genes affect health, and thus, transform health care for Veterans and for all Americans,” announced VA Under Secretary for Health Robert A. Petzel, MD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/va/48429/
The Department of Veterans Affairs will commemorate this year’s National VA Research Week from April 23 to 27. The theme, “Caring for Veterans Through Discovery & Collaboration,” will celebrate the contributions of Veterans who participate in VA research studies, as well as the accomplishments of VA investigators and their collaborators.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52324-2012-va-national-research-week-improving-veterans-lives
Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter® can improve the determination of a woman’s risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to existing risk measures. The Xpansion Interpreter Test is based on a technology breakthrough that reveals both the number and position of “interrupting” DNA sequences in the fragile X gene of the mother and more accurately estimates the likelihood that her child will have fragile X syndrome. The study will be published in the April issue of the American Journal of Medical Genetics and presented today at the 2013 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Phoenix, AZ.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60719-asuragen-xpansion-interpreter-xi-test-data-fragile-x-syndrome-autism
Strand Life Sciences (Strand) announced today the version 2.0 release of its popular next-generation sequencing (NGS) data analysis and visualization platform, Avadis NGS, under a new name: Strand NGS. Strand NGS is built on the same award winning platform as Strand and Agilent Technologies’ GeneSpring®.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400564-Avadis-NGS-becomes-Strand-NGS
